Elucida Oncology, Inc., is a research and clinical development stage company based on proprietary ultra-small C-Dots.  Using of novel Target or Clear™ technology, C-Dots are being developed and clinically studied  to find, see and treat an array of solid tumor cancers.

Developed and clinically translated by Memorial Sloan-Kettering Cancer Center and Cornell University,        C-Dots have published human safety and tumor-specific clinical data. Elucida Oncology, Inc. is currently progressing through a broad clinical trial program.

The Company is also continuing to drive a future portfolio through ongoing development of C-Dot pharmaceutical preparations for the treatment of oncologic disorders.